Cardiopulmonary Responses to Exposure to Ozone and Diesel Exhaust (DEPOZ)
Cardiopulmonary Responses to Exposure to Ozone and Diesel Exhaust With Moderate Exercise in Healthy Adults
연구 개요
상세 설명
Numerous epidemiological studies have demonstrated an association between acute and chronic exposure to air pollution and various adverse cardiopulmonary effects including mortality, respiratory tract infections, exacerbation of asthma symptoms, chronic bronchitis, ischemic heart disease, and stroke [1] and other health effects. Understanding the components responsible for these effects is difficult because ambient air pollution is a complex mixture of gases and particulate matter (PM). In this complex mixture of ambient air pollution, ozone (O3) and diesel exhaust (DE) are generally major and important components. Controlled exposure of volunteers to either pollutant have resulted in biological effects such as lung physiological changes. However it is not known if co-exposure to both pollutants, similar to polluted ambient air, can induce additive or synergistic effects. Additionally it is also uncertain if exposure to DE, or DE with O3, can alter a subsequent exposure to O3 similar to multiple day exposures that the general population receives. This study proposes to examine whether co-exposures to O3 and DE can induce additive or synergistic effects, and whether a previous DE exposure alters a response upon subsequent exposure to O3. The potential effects of O3 on cardiac electrophysiology are also not clear.
Approximately 15 healthy non-smoking volunteers between the ages of 18 and 55 will be exposed in a controlled manner to O3 (approximately mean concentration of 0.3 ppm over the 2 hr exposure period), or diesel exhaust (DE; ~300 µg/m3), or a combined O3 and DE exposure while undergoing moderate intermittent exercise at the EPA Human Studies Facility. A clean air exposure will serve as a control. Primary endpoints for evaluating health effects and surrogate responses are changes in lung function and heart rate variability. In addition, other cardiopulmonary and vascular biological endpoints will be measured, as well as markers of exposure and genetic markers of susceptibility.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27514
- US EPA Human Studies Facility
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Healthy men and women between 18 and 55 years of age
- Physical conditioning allowing intermittent, moderate exercise for 2 hours
Normal lung function:
- FVC > 75 % of that predicted for gender, ethnicity, age and height.
- FEV1 > 75 % of that predicted for gender, ethnicity, age and height.
- FEV1/FVC ratio > 75 % of predicted values.
- Oxygen saturation > 96 %.
Exclusion Criteria:
- A history of acute and chronic cardiovascular disease, chronic respiratory disease, diabetes, rheumatologic diseases, immunodeficiency state, and acute respiratory illness within 4 weeks.
- Subjects who are asthmatic or have a history of asthma.
- Allergic to chemical vapors or gases.
- Any allergic symptoms during the time of participation in the study
- Female subjects who are currently pregnant, attempting to become pregnant, or breastfeeding
- Subjects unwilling or unable to stop taking vitamin C or E or medications which may impact the results of the ozone challenge (such as, systemic steroids and beta blockers) at least 2 weeks prior to the study and for the duration of the study. Medications not specifically mentioned here may be reviewed by the investigators prior to a subject's inclusion in the study.
- Current and past smokers within 1 year.
- Uncontrolled hypertension (> 150 systolic, > 90 diastolic).
- Subjects who do not understand or speak English
- Subjects unable to perform the moderately active exercise required for the study.
- Subjects with a history of skin allergies to adhesives used in securing heart rate monitor electrodes.
- Unspecified diseases or conditions, which in the judgment of the investigator might influence the responses to the exposures, will be a basis for exclusion.
- Subjects unwilling to stop taking over-the-counter pain medications such as aspirin, Advil, Aleve or other non-steroidal anti-inflammatory medications ("NSAIDS") for 48 hr prior to the exposures and post-exposure visits.
- Subjects with a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds (ms))
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 무작위
- 중재 모델: 요인 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: Filtered air exposure
2 hr exposure to clean, filtered air with intermittent exercise
|
Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
다른 이름들:
|
|
실험적: Ozone
2 hr exposure to 300 ppb ozone with intermittent exercise
|
Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
다른 이름들:
|
|
실험적: Diesel Exhaust, No ozone
2 hr exposure to whole diesel exhaust (300 ug/m3; gases + particles) with intermittent exercise; no ozone
|
Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
다른 이름들:
|
|
실험적: Ozone + Diesel Exhaust
2 hr exposure to a combination of 300 ppb ozone an 300 ug/m3 whole diesel exhaust with intermittent exercise
|
Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Lung Function Decrement
기간: Immediately post to 24 hr post exposure
|
Lung function decrements are typically expressed as changes in FEV1 and FVC.
Measurements are made pre-exposure (defined as baseline, immediately post exposure, 1-4 hr post exposure, and 24 hr post exposure (follow up).
|
Immediately post to 24 hr post exposure
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Heart rate variability
기간: immediately post to 24 hr post exposure
|
immediately post to 24 hr post exposure
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
plasma cytokine levels
기간: immediately post to 24 hr post exposur
|
Inflammation markers such as interleukin 8
|
immediately post to 24 hr post exposur
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Michael Madden, PhD, Environmental Protection Agency (EPA)
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
혈압에 대한 임상 시험
-
Assiut University아직 모집하지 않음간질환이 있는 경우 악성종양 식별에 있어서 Blood Pool SUV Ratio의 타당도 원문보기 KCI 원문보기 인용
-
Hangzhou Agile Groups Network Technology Co., Ltd.완전한
ozone에 대한 임상 시험
-
Omaima Mossad Mahmoud AL-Sherbini완전한통증, 수술 후 | 치은 후퇴 | 환자 만족도 | 기증자 사이트 | 합병증이 없는 구개의 열린 상처 | 무료 잇몸 이식 | 점막치은 결손이집트